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ABSTRACT
Pro-inflammatory cells, cytokines, and chemokines are essential in promoting a 
tumor supporting microenvironment. Chemerin is a chemotactic protein and a natural 
ligand for the receptors CMKLR1, GPR1, and CCRL2. The chemerin/CMKLR1 axis is 
involved in immunity and inflammation, and it has also been implicated in obesity 
and cancer.
In neuroblastoma, a childhood tumor of the peripheral nervous system we 
identified correlations between high CMKLR1 and GPR1 expression and reduced overall 
survival probability. CMKLR1, GPR1, and chemerin RNA and protein were detected in 
neuroblastoma cell lines and neuroblastoma primary tumor tissue. Chemerin induced 
calcium mobilization, increased MMP-2 synthesis as well as MAP-kinase- and Akt-
mediated signaling in neuroblastoma cells. Stimulation of neuroblastoma cells with 
serum, TNFα or IL-1β increased chemerin secretion. The small molecule CMKLR1 
antagonist α-NETA reduced the clonogenicity and viability of neuroblastoma cell 
lines indicating the chemerin/CMKLR1 axis as a promoting factor in neuroblastoma 
tumorigenesis. Furthermore, nude mice carrying neuroblastoma SK-N-AS cells as 
xenografts showed impaired tumor growth when treated daily with α-NETA from day 
1 after tumor cell injection.
This study demonstrates the potential of the chemerin/CMKLR1 axis as a 
prognostic factor and possible therapeutic target in neuroblastoma.
INTRODUCTION
Neuroblastoma is a malignancy of the sympathetic 
nervous system occurring in early childhood and 
accounting for 7% of all pediatric cancers [1]. While the 
prognosis for low and intermediate risk neuroblastoma 
patients is favorable, the long-term event-free survival 
rate for high-risk patients remains less than 50%, despite 
intensive treatment [1, 2].
Chronic inflammation is an important modulator of 
the tumor microenvironment (TME). Pro-inflammatory 
cells, cytokines, and chemokines present in the TME 
promote tumor development, progression, and metastasis 
in various cancers [3, 4]. Recently, a subset of high-
risk, therapy-resistant neuroblastomas was demonstrated 
to be inflammation-driven indicating the importance 
of inflammation in neuroblastoma [5]. A thorough 
understanding of the neuroblastoma TME and the 
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inflammatory processes involved in tumorigenesis may 
lead to new therapy approaches and the discovery of novel 
prognostic markers [6–9].
Chemerin (also known as TIG-2 or RARRES2) 
is an adipokine and chemoattractant factor associated 
with obesity, inflammatory diseases and cancer [10–
20]. Synthesized as a 163 amino acid preproprotein, 
this chemerin precursor is N-terminally cleaved and 
secreted as prochemerin with low activity. Following 
secretion, prochemerin can be C-terminally cleaved by 
a variety of extracellular proteases, resulting in several 
chemerin isoforms with varying length, receptor affinity, 
and biological activity [21]. Proteases associated with 
inflammation such as cathepsin G and neutrophil elastase 
respectively cleave prochemerin into chemerin 21-156 
and 21-157. These are the most active forms, whereas 
prochemerin processed with mast cell chymase or protease 
3 results in the inactive or low activity chemerin 21-154 and 
21-155 variants, respectively [22, 23]. During inflammation 
initiation, maintenance and resolution the different 
chemerin isoforms may exert pro- and/or anti-inflammatory 
functions [24, 25]. Chemerin is a natural ligand for the 
G-protein-coupled receptors CMKLR1 (or ChemR23), 
GPR1, and CCRL2. CMKLR1 is expressed by different cell 
types including macrophages as well as immature dendritic 
cells and mediates the majority of the described chemerin 
functions [10, 24, 26–29]. Besides the involvement in 
various inflammatory diseases, the chemerin/CMKLR1 axis 
has been shown to play a role in different malignancies. 
While there is evidence that chemerin and CMKLR1 
support tumorigenesis in glioblastoma, gastric cancer, 
squamous esophageal cancer and squamous cell carcinoma 
of the oral tongue [16-18, 20], an anti-tumorigenic effect 
has been suggested in melanoma, hepatocellular carcinoma 
and non-small cell lung cancer [15, 30, 31].
GPR1 functions are so far less understood, but it 
has recently been found to contribute to the regulation of 
glucose homeostasis in obese mice [32]. At present, no 
active signaling has been detected following chemerin 
binding to CCRL2. However, CCRL2 is known to increase 
local chemerin concentrations [33] and its expression has 
been linked to rheumatoid arthritis and liver metastasis 
in colorectal cancer [34, 35]. The aim of the present 
study was to investigate the functional significance of 
chemerin, CMKLR1 and GPR1 in the neuroblastoma 
microenvironment and assess their potential as prognostic 
factors and therapeutic targets.
RESULTS
High CMKLR1 and GPR1 expression 
predict poor overall survival probability in 
neuroblastoma
To investigate CMKLR1 and GPR1 gene expression 
in neuroblastoma we used the publically available R2: 
Genomics analysis and visualization platform http://
r2.amc.nl. Examining two neuroblastoma gene expression 
cohorts, we found a correlation between high expression 
of CMKLR1 (Figure 1A and 1B) and GPR1 (Figure 1D 
and 1E) and a decrease in overall survival probability. 
Furthermore, CMKLR1 expression was higher in 
neuroblastoma cohorts compared to benign neurofibroma 
and neural crest cells (Figure 1C). However, no difference 
was found comparing GPR1 expression in the different 
cohorts (Figure 1F).
Additionally, we observed that expression 
of chemerin receptor CCRL2 was elevated in the 
neuroblastoma cohorts compared to neurofibroma and 
neural crest, and that high expression of CCRL2 correlated 
with a poor survival prognosis (Supplementary Figure 1D-
1F). While chemerin (RARRES2) expression was higher 
in the neuroblastoma cohorts compared to the neural 
crest, no difference was seen in comparison with benign 
neurofibroma. Furthermore, no clear correlation between 
high expression of RARRES2 and a decrease in overall 
survival probability was apparent due to conflicting results 
in the selected data sets (Supplementary Figure 1A-1C).
Neuroblastoma cell lines express chemerin, 
CMKLR1 and GPR1
We examined different neuroblastoma cell lines 
for the expression of CMKLR1, GPR1 and chemerin. 
Using RT-PCR (Figure 2A) and western blot (Figure 
2B) we demonstrated expression of CMKLR1, GPR1 
and chemerin mRNA and protein at varying levels 
in all neuroblastoma cell lines tested. No correlation 
was apparent between CMKLR1, GPR1 or chemerin 
expression levels and specific cell line characteristics such 
as MYCN amplification, 1p deletion, 11q deletion or multi-
drug resistance phenotype.
HepG2 cells were included in the western blots as 
a positive control. They are known to express and secrete 
chemerin and several antibody suppliers recommended 
them as a control cell line for CMKLR1.
Furthermore, we examined the expression levels 
of RARRES2 (chemerin), CMKLR1 and GPR1 in a panel 
of neuroblastoma cell lines using the publically available 
R2: Genomics analysis and visualization platform 
http://r2.amc.nl. We observed that all three genes are 
expressed at varying levels in the neuroblastoma cell 
lines included in this panel (Supplementary Figure 2A-
2C). In addition we compared their expression to known 
neuroblastoma promoting cytokines, chemokines, growth 
factors and their receptors and found GPR1 and CMKLR1 
expression in the range of FPR1, IL6R and PDGFRA. 
While RARRES2 (chemerin) expression is lower than 
VEGFA, it is comparable to CCL2 and CCL5 expression 
(Supplementary Figure 2D and 2E).
Immunofluorescence staining demonstrated the 
cellular distribution of CMKLR1 (Figure 2C) and GPR1 
(Figure 2D) in the neuroblastoma cell line SH-SY5Y. 
Both receptors were localized at the cell membrane 
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and in the cytoplasm. Comparable staining pattern for 
CMKLR1 was observed in other neuroblastoma cell lines 
using additional primary antibodies for confirmation 
(Supplementary Figure 3A and 3B). No apparent staining 
was observed in cells incubated with an isotype control 
antibody instead of the primary antibody (Supplementary 
Figure 3C).
TNFα, IL-1β and serum increase chemerin 
secretion in neuroblastoma cells
To investigate the effect of the pro-inflammatory 
cytokines TNFα and IL-1β as well as serum components 
on chemerin expression and secretion, chemerin 
concentrations were measured by ELISA. Exposure to 
IL-1β, TNFα as well as 10% serum for 24h increased the 
level of chemerin in the supernatant of SK-N-AS cells 
(Figure 2E).
CMKLR1, GPR1 and chemerin are expressed in 
neuroblastoma primary tumors
To confirm the presence of CMKLR1, GPR1 and 
chemerin in neuroblastoma primary tumors, IHC and 
IF-P were performed. A total of 27 neuroblastoma tissue 
samples from all clinical stages and biological subsets 
[36] were stained with antibodies detecting chemerin, 
CMKLR1 and GPR1. All tumor samples investigated 
demonstrated a significant expression of chemerin and its 
receptors. Figure 3 presents a representative labeling with 
CMKLR1 (Figure 3A), GPR1 (Figure 3B) and chemerin 
(Figure 3C) specific antibodies showing a clear staining of 
both the receptors and chemerin in neuroblastoma primary 
tumors. Fluorescence labeling of CMKLR1 (green) and 
chemerin (red) displayed the membranous and cytoplasmic 
localization of CMKLR1 whereas chemerin was detected 
both in intra- and extracellular compartments (Figure 
Figure 1: High CMKLR1 and GPR1 expression predicts poor survival in neuroblastoma patients. Expression data was 
analyzed using the R2 database http://r2.amc.nl. Kaplan-Meier survival estimates were used to evaluate the prognostic value of CMKLR1 
(A, B) and GPR1 (D, E) expression in two patient data sets (A and D: Versteeg n=88; B and E: Seeger n=102). The Kaplan-Meier scanning 
tool was used to determine the CMKLR1 and GPR1 mRNA expression in neuroblastoma. All expression data were scanned to find the 
most optimal cut-off between high and low gene expression and the log-rank test that gave the lowest p-value was calculated to search for 
significant differences between tumor samples expressing high and low CMKLR1 and GPR1 mRNA levels, respectively. The expression of 
CMKLR1 (C) and GPR1 (F) was compared between neural crest (Etchevers n=5), benign neurofibroma (Miller n=86) and 4 neuroblastoma 
cohorts (cohort 1: Versteeg n=88, cohort 2: Delattre n=64, cohort 3: Hiyama n=51, cohort 4: Lastowska n=30).
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3D-3F) indicating chemerin secretion in neuroblastoma 
primary tumor tissue. For both, IHC and IF-P, no apparent 
staining was observed in sections incubated with isotype 
control antibodies instead of the primary antibodies 
(Supplementary Figure 3D-3F).
Chemerin induces calcium mobilization 
and promotes MAPK and Akt signaling in 
neuroblastoma cell lines
Chemerin has been previously shown to stimulate 
intracellular calcium mobilization in immature DCs 
and macrophages as well as MAPK and Akt signaling 
in human chondrocytes and endothelial cells through 
CMKLR1 [14, 24, 37]. GPR1-mediated calcium 
mobilization and ERK1/2 phosphorylation following 
chemerin binding has been demonstrated to be much 
weaker [38, 39]. Recently, both CMKLR1 and GPR1 
were found to signal through the RhoA/Rock pathway in 
HEK293A and gastric carcinoma cells [40].
To determine the effect of chemerin in 
neuroblastoma, we studied calcium mobilization, MAPK, 
and Akt signaling in neuroblastoma cell lines. Chemerin 
stimulation caused a rapid, but transient increase in 
intracellular calcium in SK-N-SH cells (Figure 4A and 
4B) in comparison to vehicle treatment. Furthermore, 
prior incubation with the calcium chelator EDTA showed 
no inhibitory effect (Figure 4B) indicating calcium release 
from intracellular compartments.
The addition of chemerin to SK-N-AS cells induced 
a rapid and dose-dependent phosphorylation of MEK1/2, 
ERK1/2 and Akt (Figure 4C) indicating the activation 
of MAPK and Akt signaling. Similar phosphorylation 
patterns were observed in SK-N-BE(2) cells (data not 
shown).
Chemerin increases MMP-2 synthesis in 
neuroblastoma cells
Chemerin is known to stimulate MMP-2 and 
MMP-9 expression and activity [37, 41]. Using real-time 
zymography, we could follow the degradation of gelatin 
by MMP-2 and MMP-9 in real-time. We observed a dose-
dependent increase in MMP-2 synthesis in both SK-N-
Figure 2: CMKLR1, GPR1 and chemerin are expressed in neuroblastoma cell lines and TNFα, IL-1β, and serum 
stimulate chemerin secretion. (A) RT-PCR analysis demonstrating the expression of chemerin, CMKLR1 and GPR1 mRNA in all 
neuroblastoma cell lines investigated. NTC, no template control. The expression of chemerin, CMKLR1, and GPR1 protein was confirmed 
by western blot (B). HepG2 cells were used as a positive control. The images are representative of three independent experiments. 
Immunofluorescence labeling shows the presence of CMKLR1 (C) and GPR1 (D) in SH-SY5Y cells (green). The nuclei (blue) were stained 
with Hoechst 33342, scale bar 20μm. (E) Chemerin concentrations were measured in cell supernatants of SK-N-AS cells after treatment 
with 10 or 50ng/ml TNFα, IL-1β or 10% FBS for 12 or 24h, respectively. The supernatants of 10 independent samples were pooled and 
concentrated 10x prior to ELISA measurement. The standards and samples were measured in duplicates and the data is presented as mean 
and range. Statistical analysis was performed using a two-way ANOVA P<0.001 for both stimulation and incubation time followed by 
Dunnett’s post-test control vs. treatment * P<0.05, *** P<0.001.
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AS and to a lesser extent in SK-N-BE(2) cells after 6, 12, 
24 and 48h stimulation with active chemerin (Figure 5). 
No effect on MMP-9 synthesis was observed under these 
conditions.
CMKLR1 inhibition reduces the cell viability 
and clonogenicity of neuroblastoma cells
The effect of CMKLR1 inhibition on 
neuroblastoma cell lines was studied using the recently 
described CMKLR1 inhibitor α-NETA [42]. Increasing 
concentrations of α-NETA reduced the cell viability of 
four neuroblastoma cells lines after 72h of treatment with 
IC50 values ranging between 3.87-7.49μM (Figure 6A 
and 6B). No effect (IC50 values >10μM) was observed 
on human fibroblasts (MRC-5) and endothelial cells 
(HUVEC). A dose-dependent inhibition of clonogenicity 
was observed in SK-N-BE(2) cells (Figure 6C) as well 
as SK-N-AS, SK-N-DZ, and SH-SY5Y cells (Figure 6D). 
The colony forming ability was completely inhibited using 
5μM α-NETA.
Early and prolonged CMKLR1 inhibition 
impairs neuroblastoma growth in vivo
The therapeutic effect of CMKLR1 inhibition was 
examined in a SK-N-AS xenograft model. A significant 
prolongation (p=0.015, Log rank test) of survival (defined 
as time needed for the animals to grow a macroscopic 
tumor with a volume >1.5ml) was observed in the pre-
treatment group, where the animals were treated s.c. 
with α-NETA continuously from day 1 after tumor cell 
injection, compared to the control group (Figure 7). 
In addition, when comparing tumor growth rates for 
individual tumors, the tumors from the pre-treated mice 
grew significantly slower than the tumors in the control 
group (p=0.0061, one way ANOVA with Bonferroni post-
test, control vs. pre-treatment p=0.049, Supplementary 
Figure 4). However, no effect was seen in the treatment 
group, where α-NETA s.c. injections were initiated after 
the tumor reached a volume of ≥ 0.15ml, compared to 
the control group. No signs of toxicity were observed at 
the used concentrations of α-NETA. In the pre-treatment 
Figure 3: CMKLR1, GPR1 and chemerin are expressed in neuroblastoma primary tumors. Immunoperoxidase staining 
demonstrates specific expression of (A) CMKLR1, (B) GPR1 and (C) chemerin in neuroblastoma primary tumor tissue. Immunofluorescence 
labeling (D-F) displays CMKLR1 (green) and chemerin (red) localization in neuroblastoma tissue. The nuclei were stained with DAPI 
(blue). (E and F) are higher magnifications of (D) to illustrate the colocalization of CMKLR1 and chemerin. The displayed images are 
representative stainings from a panel of neuroblastoma tumors.
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group, a hardening of the skin was seen at the later stages 
of the experiment probably due to the daily s.c. injection 
over a prolonged period. All mice gained weight over the 
course of the experiment.
DISCUSSION
Neuroblastoma is a malignancy with only a few 
identified key genetic events. Besides amplification 
of the MYCN oncogene (in approximately 20% of 
neuroblastomas), ALK mutations and amplifications 
occur in 9% and 2-3%, respectively. Other affected genes 
include ODC, NTRK2/TrkB, FOXR1, PTPN11, ATRX, 
CADM1, and ARID1A/B [2, 43]. For the discovery of 
potential new therapeutic targets, understanding of the 
neuroblastoma TME is of great importance. Chemokines 
and chemoattractant factors are essential regulators of cell 
trafficking during immune response and inflammation. 
Furthermore, they are involved in all stages of cancer 
development: tumor establishment, neovascularization, 
and metastasis [44, 45].
Several chemokine receptors and their ligands 
have been identified as contributors to neuroblastoma 
angiogenesis, metastasis, and communication between 
tumor cells and cells of the TME [6, 46]. CMKLR1 
is a chemoattractant receptor present on immune cells 
such as immature DCs, macrophages and NK cells [47]. 
Recently, CMKLR1 was found to be expressed in a 
subset of myeloid-derived suppressor cells (MDSCs) in 
hepatocellular carcinoma [48].
Chemerin, a ligand for CMKLR1 possesses a wide 
variety of characteristics attributed to tumor growth such 
as chemotaxis and cell adhesion, as well as cell survival 
and proliferation [21, 41, 47]. In ECs, CMKLR1 was 
Figure 4: Chemerin induces intracellular calcium mobilization and stimulates MAPK and Akt signaling in 
neuroblastoma cells. Intracellular calcium mobilization was measured in SK-N-SH cells with confocal laser scanning microscopy 
following the stimulation with 10nM chemerin without (A) and with (B) the prior addition of the calcium chelator EDTA. The arrow 
indicates the time point when chemerin was added. (C) Chemerin stimulates the phosphorylation of Akt, ERK1/2 and MEK1/2 in SK-N-AS 
cells in a dose-dependent manner. The cells were serum-starved for 24h prior to stimulation and samples were taken 5, 10, 20 and 30min 
after stimulation. Densitometric analysis of the protein bands was performed and the ratios between p-ERK1/2 and total ERK1/2, p-Akt 
and total Akt as well as p-MEK1/2 and β-actin were calculated. The values are displayed relative to the control=1. The experiments were 
performed three times with similar results.
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found to be upregulated by the pro-inflammatory cytokines 
TNFα, IL-1β and IL-6. Furthermore, chemerin stimulation 
induced MMP production and angiogenesis [37]. Recent 
work by Chua et al. demonstrates that hypoxia promotes 
chemerin expression in human coronary artery endothelial 
cells as well as migration and tube formation, supporting 
previous findings on the role of chemerin in angiogenesis 
[49]. However, the function of the chemerin/CMKLR1 
axis in malignancies is probably tumor specific as both 
tumor promoting and tumor suppressing roles have been 
reported [15-18, 20, 30, 31].
In the present study, we investigated the role of 
chemerin and its receptors CMKLR1 and GPR1 in 
neuroblastoma tumorigenesis. Using publically available 
gene expression datasets (http://r2.amc.nl) we observed 
that high CMKLR1 and GPR1 expression correlates with 
a reduced overall survival probability in the two datasets 
we examined. We did not find any relationship between 
genetic characteristics of neuroblastoma, such as MYCN 
expression, and CMKLR1, GPR1 or chemerin expression. 
Our findings indicate that CMKLR1 and/or GPR1 could 
potentially be used as independent prognostic factors.
Tumor-associated macrophages (TAMs) have 
been shown to promote neuroblastoma tumorigenesis 
[6], and CMKLR1 expression in macrophages can be 
stimulated by mammary and lung carcinoma cells [50]. 
Asgharzadeh et al. [7] described the prognostic value of 
a TAM gene expression signature (CD33, CD16, IL6R, 
IL10, FCGR3) in metastatic neuroblastoma. Examining 
publically available neuroblastoma gene expression 
datasets (R2: Genomics Analysis and Visualization 
Platform http://r2.amc.nl) we observed a significant 
correlation between expression of CMKLR1 and the 
TAM markers (Supplementary Figure 5). IHC labeling 
of the macrophage marker CD68 as well as double IF-P 
staining of CD68 and CMKLR1 in neuroblastoma tissue 
demonstrated that while the majority of CMKLR1 is 
expressed by the tumors cells, CD68+ cells in the TME 
also express CMKLR1 (Supplementary Figure 6).
Additionally, CMKLR1 is expressed at high levels 
in monocytic MDSCs in hepatocellular carcinoma 
[48]. Therefore, the expression of CMKLR1 on tumor 
promoting immune cells could also play a significant role 
in the tumorigenesis process.
Figure 5: Chemerin stimulates MMP-2 synthesis in neuroblastoma cells. Typical real-time gelatin zymography of supernatants 
from SK-N-AS and SK-N-BE(2) cells untreated (control) or treated with increasing concentrations of chemerin (0.1-100 nM) or TNFα (10 
ng/ml) for 6h, 12h, 24h and 48h. Prior to stimulation, the cells were serum-starved for 24h. For each zymogram the supernatants of three 
independent samples were pooled and analyzed. The shown zymograms were taken after optimal incubation time (for SK-N-AS 15h, 10h, 
13h and 13h and for SK-N-BE(2) 15h, 10h, 5h and 4h) in assay buffer after the removal of SDS from the gels. The standard (st) comprised 
a mixture of proMMP-9 monomer (92 kDa), active MMP-9 (83 kDa), proMMP-2 (72 kDa) and active MMP-2 (62 kDa).
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A recent study demonstrated that chemerin secreted 
by esophageal squamous cancer-associated myofibroblasts 
stimulates the migration of cancer cells, indicating a role 
in invasion. Blockage of the chemerin/CMKLR1 axis 
inhibited invasion [41]. In addition, Kaur et al. determined 
a mitogenic effect of chemerin on human macro- and 
microvascular endothelial cells through activation of 
CMKLR1 [37]. Therefore, a potential role of chemerin/
CMKLR1 in neuroblastoma angiogenesis could be 
hypothesized. Collectively, these findings indicate that 
targeting CMKLR1 expressed on stromal cells in addition 
to the tumor cells could be of therapeutic interest.
In the present study, active chemerin induced 
both calcium mobilization and the activation of MAPK 
and Akt signaling. PI3K/Akt- and MAPK-mediated 
signaling are known to contribute to neuroblastoma 
tumorigenesis [51–54]. Furthermore, we demonstrated 
that the pro-inflammatory cytokines TNFα and IL-1β as 
well as serum components stimulate chemerin secretion by 
neuroblastoma cells. Both cytokines have been previously 
found to regulate CMKLR1 and chemerin expression 
in human endothelial cells, keratinocytes (IL-1β), and 
other cell types [37, 55]. Additionally, we observed 
that chemerin stimulated MMP-2 synthesis in a dose-
dependent manner. MMP-2 is a member of the matrix 
metalloproteinase family with important functions in 
tumorigenesis. Through processing of extracellular matrix 
and non-matrix proteins, MMP-2, and other members of 
the MMP family, contribute to cell invasion, metastasis 
and neovascularization [56]. Increased MMP-2 expression 
in neuroblastoma has been associated with increased 
angiogenesis, advanced stage, and poor clinical outcome 
[57, 58]. Our results indicate that chemerin may contribute 
to an increased MMP-2 synthesis in neuroblastoma.
Figure 6: The CMKLR1 antagonist α-NETA reduces the cell viability and clonogenicity of neuroblastoma cell lines. 
Cell viability was determined after 72h of incubation with α-NETA (0.313-10μM). A dose-dependent decrease in cell viability was observed 
in the neuroblastoma cell lines but not in MRC-5 and HUVEC cells (A). Data is presented as mean ± SEM from three experiments. The 
IC50 values are given with 95% confidence intervals in (B). The mean of log IC50s in neuroblastoma cell lines was significantly lower than 
the hypothetical log IC50 of the investigated normal cell lines (one sample t-test, p=0.029; means: 0.726 vs 1). The CMKLR1 antagonist 
α-NETA reduces the clonogenicity of SK-N-BE(2) cells (C; 1.25 and 2.5μM, n=3) and other neuroblastoma cell lines (D; 0.313-2.5μM, 
n=3) in a dose-dependent manner after 72h treatment. Data is presented as mean ± SD from a representative experiment. The experiment 
was repeated twice more with similar results. Statistical testing was performed using a two-way ANOVA P<0.001 for both stimulation and 
between cell lines followed by Dunnett’s post-test control vs. treatment * P<0.05, *** P<0.001.
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In our work, we observed that α-NETA, a small 
molecule inhibitor for CMKLR1, reduced the cell viability 
and clonogenicity of neuroblastoma cell lines. Initially 
identified as a choline acetyltransferase inhibitor, α-NETA 
was recently found to be a more potent inhibitor of 
CMKLR1 [42]. In an in vivo xenograft study, we observed 
that continuous, long-term treatment with α-NETA 
resulted in impaired tumor growth. However, no effect 
was observed when α-NETA injections were initiated 
after the tumor had reached a volume of 0.15ml. These 
results indicate that CMKLR1 function might be of greater 
importance during the early stages of tumor growth as well 
as tumor recurrence and relapse in neuroblastoma patients. 
However, SK-N-AS xenograft tumors grow very fast once 
the tumor has been established therefore providing only a 
narrow treatment window. In order to achieve a significant 
effect, a longer treatment window as given in the pre-
treatment group might be necessary. The results from the 
in vitro studies indicate a role of CMKLR1 during clone 
formation. Inhibiting CMKLR1 at a stage where the tumor 
has reached a certain size might therefore have a smaller 
impact. Since α-NETA has only recently been described 
as a CMKLR1 inhibitor, potential off-target effects are not 
fully studied. Concerning bioavailability and stability of 
α-NETA in vivo only limited data is available, hampering 
dose estimation. Hence, the concentration used in this 
study might have been too low to sufficiently abrogate 
CMKLR1 function in established tumors. Further studies 
are therefore necessary to determine the appropriate 
concentrations for α-NETA in vivo. Additionally, the 
results should be confirmed using CMKLR1 knockout 
neuroblastoma cell lines. Although we made several 
attempts to knock down/out CMKLR1 in neuroblastoma 
cell lines using both shRNA and the CRISPR/Cas9 system, 
we have established to date only one SK-N-AS cell line 
with a marked CMKLR1 downregulation (Supplementary 
Figure 7). Since this cell line grows very slowly and is 
unable to form distinct colonies in clonogenicity assays 
we have been unable to utilize it in functional in vitro or in 
vivo studies. While these findings, taken together with the 
results from the inhibitor studies, indicate that CMKLR1 
may contribute to colony formation and tumorigenesis we 
have been unable to confirm these findings with additional 
knock down clones.
GPR1 is an additional active chemerin receptor 
expressed in the central nervous system, skeletal 
muscle, and adipose tissue [47]. In this work, we also 
demonstrate the expression of GPR1 mRNA and protein 
in neuroblastoma cell lines and primary tumor tissue. 
While most of the known chemerin functions have 
been connected to CMKLR1-mediated signaling, we 
cannot exclude that chemerin mediated signaling in 
neuroblastoma cell lines is not at least partly mediated by 
GPR1. However, GPR1 mediated calcium mobilization 
and ERK1/2 phosphorylation has been demonstrated 
to be much weaker compared to CMKLR1 [38, 39]. 
Recently, chemerin was found to activate RhoA/Rock 
signaling through CMKLR1 and GPR1 [40]. The Rho/
Rock pathway is involved in actin rearrangement, hence 
suggesting a potential role of the chemerin/CMKLR1/
GPR1 axis in migration and metastasis.
CCRL2, the third known chemerin receptor is present 
on myeloid cells, mast cells and CD34+ bone marrow 
precursors [47]. While not actively signaling, it was found 
Figure 7: Early and prolonged CMKLR1 inhibition with α-NETA impairs tumor growth in vivo. Kaplan-Meier survival 
plots of nude mice (n=11 in control group and in pre-treatment group, n=10 in treatment group) injected daily s.c. with 20mg/kg α-NETA 
after the tumor reached 0.15ml (treatment group), 10mg/kg α-NETA from the day after tumor cell injection and 20mg/kg when the tumor 
reached 0.15ml (pre-treatment group) or 10% Captisol® (control group). Survival, defined as time needed for the animals to grow a 
macroscopic tumor (volume >1.5ml), was significantly prolonged in the pre-treatment group (log rank test P=0.015, control vs. pre-
treatment P= 0.019 and control vs. treatment P=0.51).
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to increase local chemerin levels suggesting that CCRL2 
presents chemerin to CMKLR1 or GPR1 on neighboring 
cells [33]. Akram et al. recently identified a role of CCRL2 
in colorectal cancer liver metastases [35]. Although we 
were able to detect CCRL2 mRNA in neuroblastoma cell 
lines (data not shown), the role of CCRL2 in neuroblastoma 
was not addressed in the present study.
Our results demonstrate, for the first time, the 
presence of a fully active and functional chemerin/
CMKLR1 axis in childhood neuroblastoma. Neuroblastoma 
cells produce chemerin that can promote survival in an 
autocrine manner. Inhibition of the chemerin/CMKLR1 axis 
impaired neuroblastoma cell growth in vitro and in vivo. 
Our findings provide new insight into the pathobiology of 
neuroblastoma. Pharmacological interventions targeting the 
chemerin/CMKLR1 signaling pathway may be an important 
adjuvant therapy for children with neuroblastoma, but 
further preclinical in vivo studies are warranted.
MATERIALS AND METHODS
Microarray gene expression analysis
Gene expression analysis was performed using 
the publicly available R2: Genomics Analysis and 
Visualization Platform (http://r2.amc.nl).
Antibodies and reagents
The antibodies used in this study are listed in Table 
1. Recombinant human IL-1β was purchased from Cell 
Guidance Systems Ltd. (Cambridge, UK). Recombinant 
human TNFα and chemerin were obtained from R&D 
Systems, Inc. (Minneapolis, USA) and α-NETA was from 
Santa Cruz Biotechnology, Inc. (Dallas, USA).
Cell lines and human tissue samples
The human neuroblastoma cell lines SK-N-
AS, SK-N-SH, SK-N-DZ, SK-N-FI, SH-EP1, Kelly, 
SH-SY5Y, and IMR-32 as well as the hepatocellular 
carcinoma cell line HepG2 were purchased from the 
ATCC (American Type Culture Collection), and SK-
N-BE(2) cells were bought from DSMZ (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen). 
The cells were cultivated in RPMI-1640 medium 
containing L-glutamine and sodium bicarbonate 
(Sigma-Aldrich Norway AS, Oslo, Norway) 
supplemented with 10% heat-inactivated FBS (Thermo 
Fisher Scientific Inc.) at 37°C in humidified air with 
5% CO2. The human fibroblast cell line MRC-5 and 
human umbilical vein endothelial cells (HUVEC) were 
purchased from the ATCC and cultivated in EGM-2 
BulletKit with 2% FBS (Lonza, Basel, Switzerland) 
Table 1: Antibodies used in the study
Antibody Application Source
Anti-ChemR23 WB, IHC #STJ92262, St John’s Laboratory
Anti-Human ChemR23 IF-P, ICC #MAB362, R&D Systems
Anti-GPCR GPR1 WB #ab157209, abcam
Anti-GPCR GPR1 ICC #ab121315, abcam
Anti-GPCR GPR1 IHC #ab188977, abcam
Anti-TIG2 Antibody (K-15) WB, IF-P #sc-47482, Santa Cruz Biotechnology
Anti-Human Chemerin IHC #MAB2324, R&D Systems
Anti-beta Actin WB #ab8227, abcam
Anti-p44/42 MAPK (Erk1/2) WB #4695, Cell Signaling Technology
Anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) WB #4370, Cell Signaling Technology
Anti-Akt WB #9272, Cell Signaling Technology
Anti-Phospho-Akt (Ser473) (D9E) WB #4060, Cell Signaling Technology
Anti-Phospho-MEK1/2 (Ser217/221) WB #9121, Cell Signaling Technology
Goat Anti-Rabbit IgG H&L (HRP) WB #ab6721, abcam
Swine Anti-Goat Ig's, HRP WB #ACI0404, Thermo Fisher Scientific
Goat anti-Rabbit IgG (H+L), Alexa Fluor 488 ICC # A-11008, Thermo Fisher Scientific
Donkey anti-Goat IgG (H+L), Alexa Fluor 594 IF-P #A-11058, Thermo Fisher Scientific
Rabbit anti-Mouse IgG (H+L), Alexa Fluor 488 IF-P # A-11059, Thermo Fisher Scientific
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and MEM supplemented with 2mM L-glutamine, 1% 
non-essential amino acids and 10% FBS, respectively. 
Mycoplasma tests were regularly performed using the 
MycoAlert™ PLUS Mycoplasma Detection Kit (Lonza, 
Basel, Switzerland).
Neuroblastoma tumor tissue was obtained from 
the Karolinska University Hospital according to the 
ethical approval from the Stockholm Regional Ethical 
Review Board and the Karolinska University Hospital 
Research Ethics Committee (approval ID 2009/1369-
31/1 and 03-736). Informed consent (written or verbal) 
was provided by the parents or guardians for the use 
of tumor samples in research. Samples were collected 
during surgery, snap-frozen in liquid nitrogen and stored 
at -80°C until further use. Twenty-seven neuroblastoma 
samples derived from children of different ages and all 
clinical stages, including different biological subsets [36] 
were analyzed.
RNA isolation and reverse transcriptase PCR
Total RNA was isolated using the RNeasy® Mini Kit 
(Qiagen Norge, Oslo, Norway) according to the provided 
manual. The RNA quantity and quality was determined 
using the NanoDrop 1000 (Thermo Fisher Scientific 
Inc.). One μg RNA was used for cDNA synthesis with 
the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories 
AB, Oslo, Norway). PCR was performed in a 25μl 
reaction mix containing 2μl cDNA, 12.5μl AccuStart™ 
II GelTrack PCR SuperMix (Quanta Biosciences, 
Gaithersburg, USA), 400 nM of each primer and 10.1μl 
of ultra-pure H2O (Biochrom GmbH, Berlin, Germany). 
The PCR run was performed in a T100™ Thermal 
Cycler (Bio-Rad Laboratories AB, Oslo, Norway) as 
follows: 2min at 94°C and 35 cycles of 94°C for 20s, 
62°C for 30s and 72°C for 90s. The sequences for the 
PCR primers were the following: APRT (housekeeping) 
5’-CCCGAGGCTTCCTCTTTGGC-3’ (sense) and 
5’-CTCCCTGCCCTTAAGCGAGG-3’ (antisense) [59], 
CMKLR1 5'-GCCAACCTGCATGGGAAAATA-3’ 
(sense) and 5’-GTGAGGTAGCAAGCTGTGATG-3’ 
(antisense), GPR1 5’-CAATCTAGCCATTGCGG 
ATTTCA-3’ (sense) and 5’-CCGATGAGATA 
AGACAGGATGGA-3’ (antisense), chemerin 
5’-AGAAACCCGAGTG CAAAGTCA-3’ (sense) and 
5’-AGAACTTGGGTCTCTATGGGG-3’ (antisense) 
(Primer bank ID 215272316c3, 148228828c3 and 
218931208c1 http://pga.mgh.harvard.edu/primerbank/
index.html).
PCR products were analyzed by gel electrophoresis. 
The 1.8% SeaKem® LE Agarose gel (Lonza) was stained 
with GelRed™ (Biotium, Inc., Hayward, USA) and 
visualized under UV light in the BioDoc-It™ Imaging 
System (UVP, LLC, Upland, USA). The PCR results for 
CMKLR1, GPR1 and chemerin were confirmed with a 
second, independent primer set (data not shown).
Western blot
Cultured cells were washed briefly with phosphate-
buffered saline (PBS, Biochrom GmbH) and harvested 
in RIPA Lysis and Extraction Buffer containing Halt™ 
Protease and Phosphatase Inhibitor Cocktail (Thermo 
Fisher Scientific Inc.). Following sonication, the 
protein concentration was determined using a Protein 
Quantification Assay (MACHEREY-NAGEL GmbH 
& Co. KG, Düren, Germany). The protein lysates were 
supplemented with NuPAGE® LDS Sample Buffer (4X) 
(Thermo Fisher Scientific Inc.) as well as 100mM DTT 
(Sigma-Aldrich Norway AS) and incubated for 10min 
at 70°C. Equal amounts of protein were separated on 
NuPAGE™ Novex™ 4-12% Bis-Tris Protein Gels (Thermo 
Fisher Scientific Inc.) and transferred onto a 0.45μm 
PVDF Membrane (Merck Life Science AS, Oslo, Norway) 
according to the XCell SureLock Mini-Cell technical guide 
(Thermo Fisher Scientific Inc.). The membranes were 
blocked in TBS-T (Tris-buffered saline (TBS) with 0.1% 
Tween-20; Sigma-Aldrich Norway AS) containing 5% 
(w/v) skimmed milk powder. Incubation with the primary 
antibody was performed overnight at 4°C according to 
antibody supplier recommendation in either blocking buffer 
or 5% BSA (AppliChem, Darmstadt, Germany) in TBS-T. 
Following three washes in TBS-T, the membranes were 
incubated in the appropriate secondary antibody solution 
for 1h at room temperature. After four washes, detection 
and visualization were performed using SuperSignal™ 
West Pico Chemiluminescent Substrate (Thermo Fisher 
Scientific Inc.) and the ImageQuant LAS 4000 imager (GE 
Healthcare, Oslo, Norway). MagicMark™ XP Western 
Protein Standard (Thermo Fisher Scientific Inc.) was used 
to estimate the molecular mass of the detected proteins. 
Densitometry was performed using Fiji software [60].
ICC
For immunocytochemistry, cells were grown on 
8-well μ-Slide (ibidi GmbH, Munich, Germany) for 
24h. Cells were then rinsed briefly with PBS and fixed 
with 4% formaldehyde for 20min. After three washes 
with PBS, unspecific binding sites were blocked with 
1% BSA in PBS containing 0.3% Triton-X-100 (Sigma-
Aldrich Norway AS) for 45min. The cells were incubated 
with primary antibodies diluted in blocking solution at 
4°C overnight. After three washes with PBS, the cells 
were incubated with the secondary antibodies diluted in 
blocking solution for 1h at room temperature, protected 
from light. Following three washes with PBS, the nuclei 
were stained with Hoechst 33342 (ImmunoChemistry 
Technologies, LLC, Bloomington, USA) for 10min. 
The cells were washed 2x with PBS and covered with 
Mounting Medium for fluorescence microscopy (ibidi 
GmbH). The cells were subsequently examined with a 
Leica TCS SP5 or Zeiss LSM780 confocal microscope.
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IHC
Formalin-fixed and paraffin-embedded tissue 
sections were deparaffinized in xylene and graded 
alcohols, hydrated and washed in PBS. After antigen 
retrieval in a sodium citrate buffer (pH 6) in a microwave 
oven, the endogenous peroxidase was blocked by 0.3% 
H2O2 for 15min. Sections were incubated overnight at 4°C 
with the primary antibody. As a secondary antibody, the 
anti-rabbit-HRP SuperPicTure Polymer detection kit (87-
9663, Zymed-Invitrogen, San Francisco, USA) or anti-
mouse EnVision-HRP (Dako, Agilent Technologies, Inc., 
Santa Clara, USA) was used. A matched isotype control 
was used as a control for nonspecific background staining.
For immunofluorescence histology studies (IF-P), 
the sections were treated as described above and stained 
sequentially with the primary and secondary antibody 
sets. Alexa Fluor® 488 and Alexa Fluor® 594 conjugated 
secondary antibodies were used to visualize positive 
staining.
The fluorescence labeled tissue sections were 
examined using the Zeiss LSM780 confocal microscope 
and the immunoperoxidase stained sections using the 
Leica DMI6000B microscope.
Calcium mobilization assay
SK-N-SH cells were seeded into an 8-well μ-Slide 
(ibidi GmbH) and incubated overnight in RPMI containing 
10% FBS. The following day the cells were washed and 
preloaded with 20μM Cal-520 (AATBio, Sunnyvale, USA) 
in Hanks' Buffer with 20mM Hepes (HHBS) with 0.04% 
Pluronic® F-127 (AATBio). After 90min of incubation 
at 37°C, the dye solution was replaced with HHBS and 
the cells were subsequently examined with a Leica TCS 
SP5 confocal microscope in the presence or absence 
2mM EDTA. Before the addition of 10nM of chemerin, 
a baseline measurement was taken. Images were then 
obtained and analyzed using the Leica LAS AF software.
Stimulation of cells with chemerin
Cells were seeded in 35mm cell culture dishes 
(Corning, Corning, USA) and incubated overnight in 
complete growth medium. The cells were serum starved 
for 24h prior to stimulation with recombinant human 
chemerin (0.1-10 nM) for 5, 10, 20 and 30min.
Chemerin ELISA
SK-N-AS cells were seeded in 96-well culture 
plates. The following day, the medium was removed 
and the cells were serum starved (0.1% FBS) overnight. 
The cells were then stimulated with either 10% FBS or 
10 ng/ml, 50 ng/ml TNFα, or IL-1β in serum reduced 
medium (0.1% FBS) for 12 and 24h. After incubation, 
supernatants from 10 parallels were pooled and spun 
for 5min at 200xg to pellet floating cells. The cell 
supernatant was concentrated 10x using Amicon Ultra-0.5 
Centrifugal Filter Unit (Merck Life Science AS). The 
chemerin quantity was assayed by ELISA according to the 
manufacturer’s instructions (Human Chemerin Quantikine 
ELISA, R&D Systems, Inc).
Real-time zymography
SK-N-AS and SK-N-BE(2) cells were seeded 
in 96-well plates (Corning, Corning, USA) and left to 
attach overnight. The medium was replaced with Opti-
MEM and the cells were serum-starved for 24h. The cells 
were thereafter exposed to chemerin (0.1-100 nM) for 6, 
12, 24 and 48h, using Opti-MEM serum-free medium. 
TNFα (10ng/ml) was used as a positive control. After 
the incubation, the medium from three independent 
samples was pooled, centrifuged at 200xg for 5min at 
4°C, and made 10 and 100mM with respect to CaCl2 
and Hepes (pH 7.5). Undiluted samples were analyzed 
for the expression of gelatin degrading enzymes using 
real-time zymography. Zymography was performed as 
described previously [61] with the exception that 0.1% 
(w/v) 2-methoxy-2,4-diphenyl-3(2H)-furanone (MDPF)-
fluorescent labeled gelatin was incorporated in the 7.5 % 
SDS-PAGE separating gel instead of 0.1% (w/v) unlabeled 
gelatin. Gelatin (Sigma-Aldrich Norway AS) was labeled 
with the fluorescent dye 2-methoxy-2,4-diphenyl-3(2H)-
furanone (Sigma-Aldrich Norway AS) to give MDPF-
gelatin as described previously [62]. The main difference 
between normal gelatin zymography and real-time gelatin 
zymography is that in real-time zymography the gel is not 
stained and hence it is possible to follow the degradation 
of the gelatin in real time without staining. In the present 
work, each gel was monitored continuously and a picture 
of the gel was taken approximately every second hour 
for fifteen hours or more. Gelatinase activity was evident 




diphenyltetrazolium bromide (MTT) viability assay [63] 
was employed to assess the effect of α-NETA on the 
viability of neuroblastoma cell lines as well as MRC-5 
and HUVEC. The cells were seeded in 96-well plates in 
full growth media. After 24h the cells were washed once 
with Opti-MEM (Thermo Fisher Scientific Inc.) before 
being incubated with 313nM-10μM α-NETA (dissolved 
in dimethylsulfoxide, DMSO) in Opti-MEM for 72h. 
Control cells received DMSO corresponding to the highest 
concentration present in the α-NETA treated cells. The MTT 
solution (20μl of 5mg MTT, Sigma-Aldrich Norway AS, 
per ml phosphate buffered saline) was added to each well. 
After 2-3h additional incubation 150μl of solution were 
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carefully removed from each well and 100μl isopropanol 
containing 0.04M HCl were added and mixed thoroughly. 
To further facilitate formazan crystal solubilizing, the plates 
were placed on an orbital shaker for 1h at room temperature. 
The absorbance was measured with a CLARIOstar plate 
reader (BMG LABTECH, Ortenberg, Germany) at 590 nm. 
The experiment was repeated three times with at least three 
parallels per treatment and the cell viability was calculated as 
the ratio of the mean OD of treated cells over vehicle treated 
control cells (100% living cells). The IC50s were calculated 
from log concentration curves using non-linear regression 
analysis in GraphPad Prism.
Clonogenic assay
SK-N-AS, SK-N-BE(2), SK-N-DZ, and SH-SY5Y 
cells were seeded in 6 well plates and allowed to attach 
to the surface overnight. The cells were washed and the 
medium was replaced with Opti-MEM containing 313 
nM-5μM α-NETA dissolved in DMSO. The control cells 
received DMSO corresponding to the highest concentration 
present in the α-NETA treated cells. After 72h the medium 
was replaced with regular growth medium containing 10% 
FBS. When the cell colonies reached ≥ 50 cells, the plates 
were briefly rinsed with PBS (Thermo Fisher Scientific 
Inc.), fixed in 4% formaldehyde (Merck Life Science 
AS), and stained with Giemsa (Merck Life Science AS). 
Colonies containing at least 50 cells were counted.
In vivo xenograft study
All animal experiments were approved by the local 
ethical committee (approval ID: N231/14) appointed 
by the Swedish Board of Agriculture and conducted in 
accordance with the local guidelines and the European 
Directive 2010/63/EU.
Female, immunodeficient nude mice (NMRI-nu/nu, 
Taconic) were used for the xenograft studies. The animals 
were housed in cages containing 2–6 mice with ad libitum 
access to food and sterile water. The cages contained 
environmental enrichment (a house, nest material and 
gnawing sticks) and the mice were kept on a 12h day/
night cycle.
Each mouse was anaesthetized (Isoflurane 
4% induction and 2% maintenance) and injected 
subcutaneously (s.c.) on the right flank with 1x107 SK-N-
AS cells. After 24h, 11 animals were randomly selected for 
the pre-treatment group and received 10 mg/kg α-NETA 
s.c. daily. α-NETA was dissolved in 10% Captisol® 
(Ligand Pharmaceuticals, Inc., La Jolla, USA). The mice 
were weighed and tumors were measured every other 
day. The tumor volume was calculated with the following 
formula: length × (width)2 × 0.44. When tumors reached 
a volume of ≥ 0.15ml the mice were randomized to either 
treatment group (20 mg/kg α-NETA, daily s.c. injections, 
n=11 in pre-treatment group and n=10 in treatment group) 
or control group (vehicle, daily s.c. injections, n=11). 
When the tumors from the pre-treatment group were ≥ 
0.15ml the α-NETA dose was increased to 20 mg/kg.
The mice were closely monitored for weight loss 
and other signs of toxicity. In accordance with the ethical 
guidelines the animals were sacrificed when tumors 
reached a volume of 2ml, or a diameter over 2cm, and 
the tumors were resected. Hence, survival was defined as 
time needed for the animals to grow a macroscopic tumor 
(volume >1.5ml). Smaller parts of the tumors were fixed 
in formaldehyde or frozen.
Tumor volume growth was analyzed using rate-
based comparison. By fitting each tumor’s growth curve 
to an exponential model (by correlating the logarithm of 
the tumor volume measurements to the time), the slope, as 
an estimate for the tumor growth, for each tumor’s growth 
could be determined [64].
Statistics
SigmaPlot and GraphPad Prism software was used 
for the statistical analysis and the graphs. Differences 
between several groups were assessed with one-way 
ANOVA and Bonferroni post-test or two-way ANOVA 
and Dunnett’s post-test. One sample t-test was used to 
compare differences between one group and a hypothetical 
mean. The survival analysis on tumor growth in vivo was 
performed using the Kaplan-Meier method and statistical 
differences between groups were performed using log-
rank test.
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